AbbVie Inc. (NYSE:ABBV) Shares Acquired by Nilsine Partners LLC

Nilsine Partners LLC increased its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 26.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,618 shares of the company's stock after purchasing an additional 1,983 shares during the quarter. Nilsine Partners LLC's holdings in AbbVie were worth $1,709,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Berkshire Bank boosted its position in shares of AbbVie by 41.2% during the fourth quarter. Berkshire Bank now owns 4,050 shares of the company's stock worth $720,000 after acquiring an additional 1,181 shares during the last quarter. Cherry Creek Investment Advisors Inc. boosted its holdings in shares of AbbVie by 0.9% during the 4th quarter. Cherry Creek Investment Advisors Inc. now owns 28,034 shares of the company's stock valued at $4,982,000 after purchasing an additional 237 shares during the last quarter. Parsons Capital Management Inc. RI grew its position in shares of AbbVie by 20.4% during the fourth quarter. Parsons Capital Management Inc. RI now owns 111,390 shares of the company's stock valued at $19,794,000 after purchasing an additional 18,865 shares in the last quarter. West Wealth Group LLC increased its holdings in shares of AbbVie by 21.8% in the fourth quarter. West Wealth Group LLC now owns 1,845 shares of the company's stock worth $328,000 after purchasing an additional 330 shares during the last quarter. Finally, Summit Financial Strategies Inc. increased its holdings in shares of AbbVie by 88.5% in the fourth quarter. Summit Financial Strategies Inc. now owns 9,457 shares of the company's stock worth $1,681,000 after purchasing an additional 4,441 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Trading Down 1.1 %

NYSE:ABBV traded down $2.02 on Tuesday, reaching $174.88. 5,603,615 shares of the company's stock were exchanged, compared to its average volume of 6,088,012. The business has a fifty day moving average of $176.05 and a 200-day moving average of $184.94. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. AbbVie Inc. has a 52-week low of $153.58 and a 52-week high of $207.32. The firm has a market capitalization of $309.04 billion, a price-to-earnings ratio of 60.72, a price-to-earnings-growth ratio of 1.68 and a beta of 0.58.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.92 by $0.08. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. The company had revenue of $14.46 billion during the quarter, compared to analysts' expectations of $14.28 billion. During the same quarter last year, the company posted $2.95 EPS. The firm's revenue was up 3.8% compared to the same quarter last year. As a group, analysts expect that AbbVie Inc. will post 10.06 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be given a dividend of $1.64 per share. The ex-dividend date is Wednesday, January 15th. This is an increase from AbbVie's previous quarterly dividend of $1.55. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.75%. AbbVie's payout ratio is currently 227.78%.

Insider Buying and Selling

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the firm's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the sale, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.25% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ABBV shares. Truist Financial cut their price target on AbbVie from $215.00 to $211.00 and set a "buy" rating for the company in a report on Wednesday, January 8th. Sanford C. Bernstein initiated coverage on shares of AbbVie in a report on Thursday, October 17th. They issued a "market perform" rating and a $203.00 target price for the company. Leerink Partnrs raised shares of AbbVie from a "hold" rating to a "strong-buy" rating in a research note on Friday, November 22nd. JPMorgan Chase & Co. dropped their price objective on shares of AbbVie from $210.00 to $200.00 and set an "overweight" rating for the company in a research note on Wednesday, November 13th. Finally, BMO Capital Markets decreased their target price on shares of AbbVie from $228.00 to $208.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 12th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $205.00.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.